BJOG : an international journal of obstetrics and gynaecology · 2026
Low-Dose Aspirin in the Prevention of Recurrent Spontaneous Preterm Birth Stratified by Placental Maternal Vascular Malperfusion: Secondary Analysis of a Randomized Trial.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Meliëzer James A L, Landman Anadeijda J E M C, Gieskes Adelia A, Bugiani Marianna, Visser Laura, Bekker Mireille N, van Laar Judith O E H, Sueters Marieke, Gordijn Sanne J, van Drongelen Joris, Sikkema J Marko, Hermes Wietske, Huisjes Anjoke J M, Papatsonis Dimitri N M, Boon Janine, Zwart Joost J, de Groot Christianne J M, Oudijk Martijn A, de Boer Marjon A
Аннотация
OBJECTIVE: To evaluate the effectiveness of low-dose aspirin in the prevention of recurrent preterm birth (PTB) in women with signs of maternal vascular malperfusion (MVM) in the placenta of the previous spontaneous PTB.
DESIGN: Secondary analysis of the APRIL study.
SETTING: The APRIL study, conducted in 34 centres in the Netherlands, evaluated low-dose aspirin versus placebo in the prevention of recurrent PTB after spontaneous PTB.
POPULATION: Women with a history of spontaneous PTB participating in the APRIL study, with available placenta histology reports from the previous spontaneous PTB.
METHODS: Placental histology reports were retrieved from participating centres and categorized for presence of MVM as defined by the Amsterdam criteria.
MAIN OUTCOME MEASURES: Recurrent PTB.
RESULTS: Placental histology reports of the previous spontaneous PTB were available for 41.3% (160/387) of participants, and MVM was present in 27.5% (44/160). In participants with MVM, recurrent PTB occurred in 4.2% (1/24) of the aspirin group, versus in 45.0% (9/20) in the placebo group (Relative Risk (RR) 0.09; 95% Confidence Interval (CI) 0.01-0.43; p = 0.02). In participants without MVM, PTB occurred in 29.3% (17/58) in the aspirin group compared to 17.2% (10/58) in the placebo group (RR 1.70; 95% CI 0.87-3.56; p = 0.13).
CONCLUSION: In women with a history of spontaneous PTB and signs of MVM in the placenta, a vascular-mediated subgroup, the use of low-dose aspirin in a subsequent pregnancy was associated with a lower rate of recurrent PTB.
DESIGN: Secondary analysis of the APRIL study.
SETTING: The APRIL study, conducted in 34 centres in the Netherlands, evaluated low-dose aspirin versus placebo in the prevention of recurrent PTB after spontaneous PTB.
POPULATION: Women with a history of spontaneous PTB participating in the APRIL study, with available placenta histology reports from the previous spontaneous PTB.
METHODS: Placental histology reports were retrieved from participating centres and categorized for presence of MVM as defined by the Amsterdam criteria.
MAIN OUTCOME MEASURES: Recurrent PTB.
RESULTS: Placental histology reports of the previous spontaneous PTB were available for 41.3% (160/387) of participants, and MVM was present in 27.5% (44/160). In participants with MVM, recurrent PTB occurred in 4.2% (1/24) of the aspirin group, versus in 45.0% (9/20) in the placebo group (Relative Risk (RR) 0.09; 95% Confidence Interval (CI) 0.01-0.43; p = 0.02). In participants without MVM, PTB occurred in 29.3% (17/58) in the aspirin group compared to 17.2% (10/58) in the placebo group (RR 1.70; 95% CI 0.87-3.56; p = 0.13).
CONCLUSION: In women with a history of spontaneous PTB and signs of MVM in the placenta, a vascular-mediated subgroup, the use of low-dose aspirin in a subsequent pregnancy was associated with a lower rate of recurrent PTB.